Physician profile
Margareth Pierre-Louis
NPI 1063731065
$438,621.20
in general payments reported to CMS, 2019-2025
12 companies · $184K in 2025
The $184K reported for 2025 was more than what 99% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $15.00 · 2022: $74K · 2023: $60K · 2024: $121K · 2025: $184K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $300K · Travel and Lodging: $35K · Consulting Fee: $28K · Food and Beverage: $1,581 · Education: $66.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $300,122.50 |
| Travel and Lodging | $35,048.83 |
| Consulting Fee | $27,775.00 |
| Food and Beverage | $1,581.36 |
| Education | $66.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $191,877.30 | 2023-2025 | Olumiant, Ebglyss |
| Abbvie INC. | $87,911.35 | 2022-2025 | |
| Galderma Laboratories, L.P. | $58,147.59 | 2024-2025 | Nemluvio |
| Pfizer INC. | $55,315.54 | 2023-2025 | |
| Janssen Scientific Affairs, LLC | $23,125.10 | 2022 | |
| Arcutis Biotherapeutics, INC. | $15,957.00 | 2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $5,456.15 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $650.00 | 2025 | Zoryve |
| Janssen Biotech, INC. | $151.04 | 2022-2023 | Tremfya |
| Organon LLC | $15.13 | 2025 | |
| Amgen INC. | $15.00 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margareth Pierre-Louis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.